

OPIOID ADDICTION AND BUPRENORPHINE TREATMENT REFERENCES

1. SAMHSA. [Physician and Program Data](#). *SAMHSA.gov*. 2018.
2. Madras BK, Wilson MC, Avula D, et al. [Screening, brief interventions, referral to treatment \(SBIRT\) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and six months](#). *Drug Alcohol Depend*. 2010;99(1-3):280-295.
3. SAMHSA. [Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health](#). *SAMHSA.gov*. 2017.
4. Stanton A, McLoed C, Luckey B, et al. [SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program](#). 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
5. Egan JE, Casadonte P, Gartenmann T, et al. [The Physician Clinical Support System-Buprenorphine \(PCSS-B\): a novel project to expand/improve buprenorphine treatment](#). *J Gen Intern Med*. 2010;25(9):936-941.
6. SAMHSA. [Number of DATA Certified Physicians](#). *SAMHSA.gov*. 2015.
7. Chychula NM, Sciamanna C. [Help substance abusers attain and sustain abstinence](#). *Nurse Pract*. 2002;27(11):30-47.
8. Alford DP, Labelle CT, Kretsch N, et al. [Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience](#). *Arch Intern Med*. 2011;171(5):425-431.
9. ASAM. [The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use](#). June 2015.
10. SAMHSA. [Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update](#). Winter 2016.
11. SAMHSA. [Methadone](#). *SAMHSA.gov*. 2015.
12. Office of National Drug Control Policy. [Medication-Assisted Treatment for Opioid Addiction](#). 2012.
13. Martin J. [Personal Communication Re: Number of Patients Maintained on Buprenorphine](#). 2011.
14. Maxwell JC, McCance-Katz EF. [Indicators of buprenorphine and methadone use and abuse: what do we know?](#). *Am J Addict*. 2010;19(1):73-88.
15. Drug Enforcement Administration (DEA). [Buprenorphine](#). 2013.
16. Sullivan L, Fiellin D. [Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice](#). *Ann Intern Med*. 2008;148(9):662-670.
17. Drugs.com. [Buprenorphine/Naloxone](#). 2017.

18. Blueshift Research. [Camurus and Indivior Set to Significantly Sway the Opioid Abuse Treatment Market](#). Blueshift Research Report; 2017.
19. Sokol Randi, Albanese Chiara, Chaponis Deviney, et al. *Why Use Group Visits for Opioid Use Disorder Treatment in Primary Care? A Patient-Centered Qualitative Study.. Subst Abuse*. 2018;39(1):52-58. [doi:10.1080/08897077.2017.1356792](https://doi.org/10.1080/08897077.2017.1356792).
20. Roll David, Spottswood Margaret, Huang Hsiang. *Using Shared Medical Appointments to Increase Access to Buprenorphine Treatment.. J Am Board Fam Med JABFM*. 2015;28(5):676-677. [doi:10.3122/jabfm.2015.05.150017](https://doi.org/10.3122/jabfm.2015.05.150017).
21. ASAM. [Advancing access to addiction medications](#). 2013.
22. Szabo L. [Addiction treatment hard to find, even as overdose deaths soar](#). *USA Today*. 2015.
23. Walden Greg. [H.R.6 - 115th Congress \(2017-2018\): SUPPORT for Patients and Communities Act](#). October 2018.